ES2970784T3 - Compuestos que modulan la función del receptor de AMPA - Google Patents
Compuestos que modulan la función del receptor de AMPA Download PDFInfo
- Publication number
- ES2970784T3 ES2970784T3 ES19710107T ES19710107T ES2970784T3 ES 2970784 T3 ES2970784 T3 ES 2970784T3 ES 19710107 T ES19710107 T ES 19710107T ES 19710107 T ES19710107 T ES 19710107T ES 2970784 T3 ES2970784 T3 ES 2970784T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- alkyl
- mmol
- disorder
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803340.7A GB201803340D0 (en) | 2018-03-01 | 2018-03-01 | Compounds |
| PCT/GB2019/050578 WO2019166822A1 (en) | 2018-03-01 | 2019-03-01 | Compounds that modulates ampa receptor function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2970784T3 true ES2970784T3 (es) | 2024-05-30 |
Family
ID=61903711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19710107T Active ES2970784T3 (es) | 2018-03-01 | 2019-03-01 | Compuestos que modulan la función del receptor de AMPA |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11298345B2 (enExample) |
| EP (1) | EP3759092B1 (enExample) |
| JP (1) | JP7225255B2 (enExample) |
| KR (2) | KR20250093578A (enExample) |
| CN (1) | CN112004811B (enExample) |
| AU (1) | AU2019226718C1 (enExample) |
| BR (1) | BR112020017739A2 (enExample) |
| CA (1) | CA3091783A1 (enExample) |
| DK (1) | DK3759092T3 (enExample) |
| ES (1) | ES2970784T3 (enExample) |
| FI (1) | FI3759092T3 (enExample) |
| GB (1) | GB201803340D0 (enExample) |
| MX (1) | MX2020009097A (enExample) |
| PL (1) | PL3759092T3 (enExample) |
| RU (1) | RU2020127537A (enExample) |
| WO (1) | WO2019166822A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| RU2279428C2 (ru) | 2000-09-18 | 2006-07-10 | Эйсай Ко., Лтд. | Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| TW200812975A (en) | 2006-03-20 | 2008-03-16 | Glaxo Group Ltd | Compounds which potentiate AMPA receptor and uses thereof in medicine |
| ATE543798T1 (de) | 2006-04-24 | 2012-02-15 | Lilly Co Eli | Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 |
| TW200817385A (en) | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| EP2086643B1 (en) | 2006-11-03 | 2011-03-23 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| GB0711088D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| JP5451611B2 (ja) | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| NZ584098A (en) | 2007-09-20 | 2012-05-25 | Cortex Pharma Inc | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) * | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| AU2010264095B2 (en) | 2009-06-26 | 2013-07-11 | Biogen Ma Inc. | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| WO2011132051A2 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2018
- 2018-03-01 GB GBGB1803340.7A patent/GB201803340D0/en not_active Ceased
-
2019
- 2019-03-01 KR KR1020257019599A patent/KR20250093578A/ko active Pending
- 2019-03-01 EP EP19710107.4A patent/EP3759092B1/en active Active
- 2019-03-01 DK DK19710107.4T patent/DK3759092T3/da active
- 2019-03-01 KR KR1020207025799A patent/KR102821949B1/ko active Active
- 2019-03-01 MX MX2020009097A patent/MX2020009097A/es unknown
- 2019-03-01 BR BR112020017739-3A patent/BR112020017739A2/pt unknown
- 2019-03-01 US US16/970,394 patent/US11298345B2/en active Active
- 2019-03-01 PL PL19710107.4T patent/PL3759092T3/pl unknown
- 2019-03-01 JP JP2020544266A patent/JP7225255B2/ja active Active
- 2019-03-01 FI FIEP19710107.4T patent/FI3759092T3/fi active
- 2019-03-01 RU RU2020127537A patent/RU2020127537A/ru unknown
- 2019-03-01 AU AU2019226718A patent/AU2019226718C1/en active Active
- 2019-03-01 CA CA3091783A patent/CA3091783A1/en active Pending
- 2019-03-01 CN CN201980016394.0A patent/CN112004811B/zh active Active
- 2019-03-01 WO PCT/GB2019/050578 patent/WO2019166822A1/en not_active Ceased
- 2019-03-01 ES ES19710107T patent/ES2970784T3/es active Active
-
2022
- 2022-03-04 US US17/687,296 patent/US12383540B2/en active Active
-
2025
- 2025-06-13 US US19/238,079 patent/US20250375432A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250375432A1 (en) | 2025-12-11 |
| EP3759092A1 (en) | 2021-01-06 |
| EP3759092B1 (en) | 2023-12-20 |
| CN112004811A (zh) | 2020-11-27 |
| AU2019226718A1 (en) | 2020-09-03 |
| JP7225255B2 (ja) | 2023-02-20 |
| PL3759092T3 (pl) | 2024-04-08 |
| BR112020017739A2 (pt) | 2020-12-22 |
| AU2019226718A8 (en) | 2020-09-24 |
| JP2021515749A (ja) | 2021-06-24 |
| DK3759092T3 (da) | 2024-01-22 |
| KR20250093578A (ko) | 2025-06-24 |
| WO2019166822A1 (en) | 2019-09-06 |
| US20230000847A1 (en) | 2023-01-05 |
| FI3759092T3 (fi) | 2024-01-18 |
| AU2019226718C1 (en) | 2024-01-11 |
| KR20200128032A (ko) | 2020-11-11 |
| GB201803340D0 (en) | 2018-04-18 |
| AU2019226718B2 (en) | 2023-09-28 |
| RU2020127537A (ru) | 2022-04-26 |
| CN112004811B (zh) | 2023-09-22 |
| US20210113539A1 (en) | 2021-04-22 |
| CA3091783A1 (en) | 2019-09-06 |
| MX2020009097A (es) | 2020-10-08 |
| NZ767186A (en) | 2025-02-28 |
| US12383540B2 (en) | 2025-08-12 |
| US11298345B2 (en) | 2022-04-12 |
| KR102821949B1 (ko) | 2025-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104870448B (zh) | 三唑并吡嗪 | |
| EP3033335B1 (en) | Pyridinones | |
| US20250375432A1 (en) | Compounds that modulates ampa receptor function | |
| JP2010524962A (ja) | オーロラキナーゼ阻害剤のための創薬法 | |
| AU2017226004A1 (en) | Inhibitors of WDR5 protein-protein binding | |
| TW201605827A (zh) | 新穎雙－醯胺吡啶 | |
| CN109071434A (zh) | 酰基磺酰胺NaV1.7抑制剂 | |
| KR102665887B1 (ko) | Ampa 수용체 강화제 | |
| CA3218951A1 (en) | Degraders of wild-type and mutant forms of lrrk2 and uses thereof | |
| HK40044378B (en) | Compounds that modulates ampa receptor function | |
| HK40044378A (en) | Compounds that modulates ampa receptor function | |
| CA3051647C (en) | Ampa receptor potentiators | |
| BR112019016603B1 (pt) | Composto, uso deste e uma formulação farmacéutica |